Involvement of long noncoding RNAs in the pathogenesis of autoimmune diseases

Yaoyao Zou a, Hanshi Xu b,*

a Department of Rheumatology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
b Department of Rheumatology and Immunology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

ARTICLE INFO

Keywords:
Long noncoding RNAs
Epigenetic regulation
Autoimmune diseases

ABSTRACT

Autoimmune diseases are a group of heterogeneous disorders characterized by damage to various organs caused by abnormal innate and adaptive immune responses. The pathogenesis of autoimmune diseases is extremely complicated and has not yet been fully elucidated. Long noncoding RNAs (lncRNAs), which are defined as transcripts containing more than 200 nucleotides with no protein-coding capacity, are emerging as important regulators of gene expression via epigenetic modification, transcriptional regulation and posttranscriptional regulation. Accumulating evidence has demonstrated that lncRNAs play a key role in the regulation of immunological functions and autoimmunity. In this review, we discuss various molecular mechanisms by which lncRNAs regulate gene expression and recent findings regarding the involvement of lncRNAs in many human autoimmune diseases, including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc) and Sjögren’s syndrome (pSS).

1. Introduction

Autoimmune diseases are a group of heterogeneous disorders that are caused by inappropriate immune responses to ‘self’ antigens; these immune responses attack normal molecules, cells and tissues of the human body, thereby causing damage to various organs and systems. Autoimmune diseases comprise a wide spectrum of complicated diseases, mainly including rheumatoid arthritis (RA), ankylosing spondylitis (AS), systemic lupus erythematosus (SLE), idiopathic inflammatory myopathy (IIM), systemic sclerosis (SSc) and Sjögren’s syndrome (pSS), and the clinical manifestations of these diseases vary from mild skin rashes to severe multiple organ dysfunction. As the pathological process of autoimmune diseases is complicated and not yet fully elucidated, the early diagnosis and efficient treatment of most autoimmune diseases have been a challenge for clinicians. Hence, further understanding of the underlying molecular mechanisms and defining the crucial regulators in autoimmune diseases are imperative (see Table 1).

The pathogenesis process of autoimmune diseases involves abnormal regulation of the immune system and cellular activity. For decades, our understanding of autoimmunity has been limited to the world of proteins; however, with the advance of the noncoding RNA (ncRNA) research field, it is increasingly apparent that this knowledge is currently incomplete. Emerging evidence indicates that long noncoding RNAs (lncRNAs) play important roles in epigenetic modification, transcriptional regulation and posttranscriptional regulation and that these molecules participate in various human diseases, especially cancers and inflammatory disorders [1–3].

Here, we will review and summarize the lncRNAs involved in the pathogenesis of autoimmune diseases and the underlying molecular mechanisms. In addition, we will emphasize the clinical relevance of lncRNAs in the diagnosis and prognosis of autoimmune diseases and the possibility that some lncRNAs may be promising targets for novel treatment strategies.

2. Long noncoding RNAs (lncRNAs)

With the completion of the human genome project and the development of high-throughput genomic sequencing technologies, ncRNA has attracted increasing attention. Previous studies have surprisingly revealed that although the majority of the human genome is transcribed, less than 2% of the human genome encodes proteins, and the remainder encodes ncRNAs [4]. For a long time, ncRNAs, which account for the majority of various transcripts, have been considered to be the ‘noise’ produced in the process of transcription and have been overlooked.
Table 1
Summary of lncRNAs involved in autoimmune diseases.

| Autoimmune disease | lncRNA | Species | Tissue/cell | Expression level | Function | Ref |
|---------------------|--------|---------|-------------|-----------------|----------|-----|
| RA                  | Hotair, LUST, anti-NOS2A, MEG9, SNHG4, TUG1, NEAT1 | Human | Serum exosome | Up-regulated | – | [51] |
| Malat1, SNHG1, mascRNA, PR antisense transcripts, PRINS, HOXA3as | | | | Down-regulated | | |
| Hotair, LUST, H19 antisense, anti-NOS2A, MEG9, SNHG4, HAR1B, TUG1, NEAT1, and GASS | | | | Up-regulated | | |
| DHFR upstream transcripts, Jpx, KRASP1, mascRNA, PR antisense transcripts, PRINS, and HOXA3as | | | | Down-regulated | | |
| ENST00000483588 | Human FLSs | Up-regulated | Positively correlated with CRP and the Simplified Disease Activity Index score (SDAI). | [53] |
| lnc-AL928768.3, lnc-AC091493.1 | Human Synovium tissue | Up-regulated | Positively associated with CRP and disease activity score in 28 joints (DAS28) | [54] |
| U75927, XR_008357, MRAK046251, DXQ66363, XR_006457, MRAK003448 | AA rat Synovium tissue | Up-regulated | | | [59] |
| HOTAIR | | | | Regulates macrophage migration. | | |
| DHFR upstream transcripts, Jpx, KRASP1, mascRNA, PR antisense transcripts, PRINS, and HOXA3as | | | | Down-regulated | | |
| HOTAIR | Human PBMC | Up-regulated | Regulates MMP-2 and MMP-13 level. | [51] |
| DHFR upstream transcripts, Jpx, KRASP1, mascRNA, PR antisense transcripts, PRINS, and HOXA3as | | | | Regulates proliferation and inflammation of chondrocytes. | [63] |
| HIX03209 | Human PBMC, macrophage | Up-regulated | Increase inflammation by sponging miR-6089 | [64] |
| NTT | Human PBMC, monocyte | Up-regulated | Promotes monocyte differentiation by regulating nearby gene PBOV1. | [65] |
| Lnc-P21 | Human Whole blood | Down-regulated | Regulates NF-kB activity. | [67] |
| LOCI00652951, LOCI0056036 | Human T cell | Up-regulated | Regulates inflammation response. | [68] |
| GASS, THRIL, RMRP | Human T cell | Up-regulated – | Induced by serum starvation and under control of PI3K and ERK pathway. | [74] |
| H19 | Human Synovial tissue, FLS, macrophage | Down-regulated | Regulates migration, invasion and proliferation by interacting with hnRNPQ. | [41] |
| LERFS | Human Synovial tissue, FLS | Up-regulated | Regulates migration, invasion by suppressing miR-27a. | [76] |
| AFAS1 | Human FLS | Up-regulated | Regulates migration, invasion by suppressing miR-382–5p and miR-575. | [77] |
| GAPLINC | Human FLS | Up-regulated | Regulates migration, invasion and proliferation by sponging miR-4701–5p. | [78] |
| PCISAR | Human FLS | Down-regulated | Regulates inflammation via targeting NLRC5. | [79] |
| FER1L4 | Human Synovial tissue, FLS | Down-regulated | Responsible for the quercetin-induced apoptosis. | [80] |
| MALAT1 | Human Quercetin-treated FLS | Up-regulated | | | |
| UCA1 | Human FLS | Down-regulated | Regulates apoptosis by Wnt6 | [81] |
| DILC | Human FLS, plasma | Down-regulated | Regulates apoptosis and IL-6 expression. | | |
| Lnc-IL7R | Human FLS | – | Promotes growth of RA FLS through interaction with EZH2 | [83] |
| LJNC00152 | Human FLS | Up-regulated | Regulates proliferation and apoptosis via Wnt/beta-catenin signaling pathway | [84] |
| GASS, THRIL, RMRP | Human T cell | Down-regulated | Regulates apoptosis and IL-18 expression. | [85,86] |
| ITSN1-2 | Human FLS | Up-regulated | Regulates apoptosis, proliferation and inflammation by NOD2/RIP2 pathway. | [87] |
| PVT1 | Rat FLS | Up-regulated | Regulates inflammation response and apoptosis. | [90] |
| MEG3 | Rat FLS | Down-regulated | Regulates proliferation by targeting NLRC5 | [88] |
| MEG3 | Human FLS, chondrocyte | Down-regulated | Inhibit proliferation and inflammation | [84] |
| CST1incRNA | Human FLS | Up-regulated | Influences the transcript levels of C5. | [71] |

(continued on next page)
| Autoimmune disease | IncRNA | Species | Tissue/cell | Expression level | Function | Ref |
|--------------------|--------|---------|-------------|------------------|----------|-----|
| SLE                | NR024118 | Mouse | Various tissues, PBMC | Up-regulated | Regulates inflammation response. | [91] |
|                    | uc001yk1.1 | Human | FLS | Down-regulated | Correlates with ESR and CRP. | [95] |
|                    | ENST00000448942 | Human | T cell | Down-regulated | Correlates with ESR and anti-Sm antibodies. | [95] |
|                    | linc0597, linc0640, and linc5150 | Human | Plasma | Up-regulated | Biomarkers of SLE | [97] |
|                    | GASS and Inc7074 | Human | Plasma | Down-regulated | Biomarkers of SLE | [97] |
|                    | ENST00000604411.1, ENST0000051122.2 linc-HSFY2-3:3 | Human | DC | Up-regulated | Positively correlated with the SLEDAI score. | [96] |
|                    | Inc-HSFY2-3:3, Inc-SERPINB9-1:2 | Human | DC | Down-regulated | – | [96] |
|                    | NEAT1 | Human | PBMCs, monocytes | Up-regulated | Correlates with SLEDAI | [98] |
|                    | GASS | Human, mouse | CD4+ T cells, B cells, plasma Monocytes | Down-regulated | Regulate IL21 expression. | [100, 104–106] |
|                    | MALAT 1 | Human | PBMC | Up-regulated | Correlates with C3 level and SLEDAI and incidence of LN. | [106] |
|                    | Linc0949 | Human | - | Down-regulated | – | [106] |
|                    | Linc-DC | Human | plasma | Down-regulated | – | [106] |
|                    | Linc0597 | Human | PBMC | Up-regulated | – | [106] |
|                    | TUG1 | Human | PBMC | Down-regulated | – | [106] |
|                    | TUG1 | Human | Kidney | Upregulated | Involved in the protection of NF-kappaB inhibition on kidney injury. | [112] |
|                    | RP11-2B6.2 | Human | Kidney biopsies from LN patients | Up-regulated | Regulates IFN-1 pathway through epigenetic inhibition of SOCS1. | [113] |
|                    | IncRNA 7 S L | Human | Serum | – | Autoantibody against IncRNA 7 S L is related to PM/DM. | [115] |
|                    | ENST00000541196.1, uc011ihb.2, linc-DGCR6-1, ENST00000551761.1, ENST00000583156.1 | Human | Muscle | Down-regulated | – | [116] |
|                    | H19, lincMyoD, MALAT1 | Human | Muscle | Down-regulated | – | [116] |
|                    | lncRNA CYP2C9 | Human | plasma | Down-regulated | – | [116] |
|                    | Linc-DC | Human | PBMC | Down-regulated | – | [116] |
|                    | TUG1 | Human | PBMC | Down-regulated | – | [116] |
|                    | TUG1 | Human | Kidney | Upregulated | Involved in the protection of NF-kappaB inhibition on kidney injury. | [112] |
|                    | RP11-2B6.2 | Human | Kidney biopsies from LN patients | Up-regulated | Regulates IFN-1 pathway through epigenetic inhibition of SOCS1. | [113] |
|                    | IncRNA 7 S L | Human | Serum | – | Autoantibody against IncRNA 7 S L is related to PM/DM. | [115] |
|                    | ENST00000541196.1, uc011ihb.2, linc-DGCR6-1, ENST00000551761.1, ENST00000583156.1 | Human | Muscle | Down-regulated | – | [116] |
|                    | H19, lincMyoD, MALAT1 | Human | Muscle | Down-regulated | – | [116] |
|                    | lncRNA CYP2C9 | Human | plasma | Down-regulated | – | [116] |
|                    | Linc-DC | Human | PBMC | Down-regulated | – | [116] |
|                    | TUG1 | Human | PBMC | Down-regulated | – | [116] |
|                    | TUG1 | Human | Kidney | Upregulated | Involved in the protection of NF-kappaB inhibition on kidney injury. | [112] |
|                    | RP11-2B6.2 | Human | Kidney biopsies from LN patients | Up-regulated | Regulates IFN-1 pathway through epigenetic inhibition of SOCS1. | [113] |
|                    | IncRNA 7 S L | Human | Serum | – | Autoantibody against IncRNA 7 S L is related to PM/DM. | [115] |
|                    | ENST00000541196.1, uc011ihb.2, linc-DGCR6-1, ENST00000551761.1, ENST00000583156.1 | Human | Muscle | Down-regulated | – | [116] |
|                    | H19, lincMyoD, MALAT1 | Human | Muscle | Down-regulated | – | [116] |
|                    | lncRNA CYP2C9 | Human | plasma | Down-regulated | – | [116] |
|                    | Linc-DC | Human | PBMC | Down-regulated | – | [116] |
|                    | TUG1 | Human | PBMC | Down-regulated | – | [116] |
|                    | TUG1 | Human | Kidney | Upregulated | Involved in the protection of NF-kappaB inhibition on kidney injury. | [112] |
|                    | RP11-2B6.2 | Human | Kidney biopsies from LN patients | Up-regulated | Regulates IFN-1 pathway through epigenetic inhibition of SOCS1. | [113] |
|                    | IncRNA 7 S L | Human | Serum | – | Autoantibody against IncRNA 7 S L is related to PM/DM. | [115] |
|                    | ENST00000541196.1, uc011ihb.2, linc-DGCR6-1, ENST00000551761.1, ENST00000583156.1 | Human | Muscle | Down-regulated | – | [116] |
|                    | H19, lincMyoD, MALAT1 | Human | Muscle | Down-regulated | – | [116] |
|                    | lncRNA CYP2C9 | Human | plasma | Down-regulated | – | [116] |
|                    | Linc-DC | Human | PBMC | Down-regulated | – | [116] |
|                    | TUG1 | Human | PBMC | Down-regulated | – | [116] |
|                    | TUG1 | Human | Kidney | Upregulated | Involved in the protection of NF-kappaB inhibition on kidney injury. | [112] |
|                    | RP11-2B6.2 | Human | Kidney biopsies from LN patients | Up-regulated | Regulates IFN-1 pathway through epigenetic inhibition of SOCS1. | [113] |
Recently, observations made by human genome-wide association studies (GWASs) found that more than 90% of disease-related SNPs are associated with noncoding elements of the genome, indicating that mutations in ncRNAs may explain some disease phenotypes [5]. Among the various kinds of ncRNAs, lncRNAs have recently become a major focus of research about disorders including autoimmune diseases.

lncRNAs, which are defined as transcripts at least 200 nucleotides in length without protein-coding potential, were first described as a new kind of transcript during the large-scale sequencing of full-length murine cDNA libraries in 2002 [6]. Most lncRNAs are transcribed by RNA polymerase (Pol) Pol II/Pol I, and some are transcribed by RNA Pol III [7,8]. The number of lncRNAs in humans has been estimated to be more than 100,000 [9]. Compared to messenger RNAs (mRNAs), lncRNAs tend to be expressed at relatively low levels [10,11], causing difficulty in detection and analysis. As shown by recent studies, most lncRNAs exhibit weak primary sequence conservation. Instead, many lncRNAs are observed to form well-conserved RNA secondary structures [12], which participate in coordination of RNA–RNA, RNA–protein and RNA–DNA interactions.

lncRNAs are exquisitely regulated and specifically expressed in many different organs, tissues, cell types and subcellular compartments [13]. Moreover, the expression of lncRNAs varies between different developmental stages [14] or disease states [2], suggesting that lncRNAs are critical regulators in cellular processes and disease progression. In fact, dozens of lncRNAs have been proven to be involved in the etiology of many human diseases [2,15,16].

2.1. Classification of lncRNAs

lncRNAs are often categorized by their position relative to nearby protein-coding genes, i.e., intergenic, antisense, intronic, or bidirectional (Fig. 1). Intergenic lncRNAs (also termed large intervening noncoding RNAs or lincRNAs) are lncRNAs located between protein-coding genes with separate transcriptional units. Antisense lncRNAs are lncRNAs that are transcribed in the opposite direction of nearby protein-coding genes and span at least one exon. Intronic lncRNAs are lncRNAs that originate from intronic regions without overlapping any exons. Finally, bidirectional lncRNAs are transcripts that initiate in a divergent fashion from the promoter of nearby protein-coding genes [17–19]. lncRNA transcripts can directly interact with proteins, DNA, and other RNAs to regulate their target molecules. Nevertheless, not all lncRNAs exert their regulatory function depending on the lncRNA molecule itself, and the processes of lncRNA transcription and/or splicing also exhibit functional roles [20,21]. According to the targets regulated by lncRNAs, we can classify lncRNAs into 2 different groups: (i) lncRNAs acting in cis, which influence the expression and/or chromatin state of nearby genes, and (ii) lncRNAs acting in trans, which leave the site of transcription and execute regulatory functions throughout the cell [22]. Recent studies have demonstrated that some lncRNAs are also capable of encoding peptides such as myoeregulin [23] and SPAR [24], which execute biological functions. This type of lncRNA is not discussed further in this review.

2.2. Molecular mechanisms of lncRNAs

The molecular functions of lncRNAs are diverse and complicated, and several mechanisms of lncRNA regulation have been proposed to date. It is well accepted that lncRNAs can serve as signals, decoys, guides, and scaffolds to perform various functions in a wide array of biological processes at the epigenetic, transcriptional and posttranscriptional levels [25,26] (Fig. 2).

2.2.1. Chromatin modification

Chromatin modification plays an important role in the regulation of gene expression. One of the first lncRNAs reported to regulate epigenetic modification was HOTAIR (HOX antisense intergenic RNA); this lncRNA acts as a scaffold that recruits chromatin modifying complexes PRC2 (polycomb repressive complex 2) to the HOXD locus, coordinates H3K27 methylation and H3K4me2 demethylation of target genes, and contributes to maintaining a repressive chromatin state [27], which has been implicated in the pathogenesis of several kinds of cancers, including breast cancer, lung cancer, and colon cancer [28]. On the other hand, HOTTIP, which is transcribed from a locus upstream of HOXA genes, recruits the MLL-1/WDR5 complex to the 5’ region of HOXA genes, mediates H3K4me3 modification and activates transcription of the HOXA locus [29].
2.2.2. Transcription control

The initiation of transcription involves the coordination of various processes and factors, including the recruitment of RNA polymerase-II (Pol II), localization and function of transcription factors, integration of different kinds of coregulators at the promoter regions of specific genes, and function of transcriptional enhancers. lncRNAs have been described to modulate transcription processes in both lncRNA transcript sequence-dependent and transcription- or splicing-dependent manners.

As demonstrated before, the splicing and transcription of the lncRNA Blustr regulates the expression of its nearby protein-coding gene Sfmbt2 by recruiting polymerases and chromatin modifiers in a mechanism that is independent of the sequence of Blustr itself [30]. In addition, emerging evidence has shown that DNA elements within the lncRNA promoter or gene locus may function as important cis-acting enhancer elements [30]. The promoter of the lncRNA downstream of the Cdkn1b (Lockd) locus was found to harbor many enhancer-like elements, through which the transcription of its neighboring gene Cdkn1b is positively regulated [31]. Another mechanism of lncRNA function is that lncRNAs interact with transcription factors or transcriptional coactivators, thereby influencing their localization and ability to bind to the promoter region of target genes. For example, the lncRNA Lethe, derived from pseudogenes, associates with the NF-kB p65 (RelA) subunit to inhibit its binding to the promoters of TNF-α, IL-6 and IL-8 [32]. The lncRNA THRIL modulates TNFα expression by interacting with hnRNP L, which is critical for the transcriptional activation of TNF-α gene [33].

2.2.3. Posttranscription regulation

In addition to being critical regulators of gene expression, lncRNAs are also important players in posttranscriptional regulatory networks. One of the most recognized mechanisms is that lncRNAs work as competitive endogenous RNAs (ceRNAs), or ‘microRNA sponges’, to reduce the levels of microRNAs and therefore regulate the expression of their target genes [34]. For instance, by binding to miR-133 and miR-135, the lncRNA linc-MD1 exquisitely modulates the expression of MAML1 and MEF2C, which control muscle differentiation [35]. Likewise, lncRNAs can also bind to mRNAs and control mRNA stability and translation activity. Previous research shows that the antisense RNA BACE1AS interacts with the BACE1 transcript, increases the stability and abundance of the BACE1 mRNA, and thus increases the expression level of the BACE1 protein [36]. In addition, lncRNAs also associate with proteins and influence posttranslational modifications such as phosphorylation [37,38] and ubiquitination [39], consequently influencing the localization, activity and degradation of the corresponding proteins. For instance, the lncRNA NRON regulates the dephosphorylation and nuclear import of activated T-cell nuclear factor (NFAT) by forming a NRON-NEAT complex [40]. Another classic example of this mechanism is the regulation of STAT3 phosphorylation by lnc-DC [37]. A recent study reported a novel lncRNA, LERFS, that regulates the expression and activity of RhoA, Rac1 and CDC42, probably by binding to hnRNP Q [41]; this finding reinforces the notion that lncRNAs may be the critical ‘reprogrammer’ at the posttranscriptional level.

### 3. Important roles of lncRNAs in autoimmune diseases

lncRNAs are widely accepted as emerging players in gene regulation and disease pathogenesis and have been intensively studied in the context of cancer [42,43], inflammation [44], and innate and adaptive immunity [18]. Herein, we provide a brief overview of the lncRNAs involved in the pathogenesis of common autoimmune diseases and discuss their potential as targets of new strategies for the diagnosis and treatment of autoimmune diseases.
3.1. lncRNAs in RA

RA is a chronic systemic autoimmune disease that is characterized by multiple symmetrical joint inflammation and progressive bone and cartilage destruction [45]. As one of the most common rheumatic diseases, RA has been a heavy burden to human health because it causes joint destruction and physical disability; however, despite intensive research in the field, the etiology and pathogenesis of RA is not yet fully understood [46]. Dysregulated immune responses [47], release of proinflammatory cytokines (such as IL-6, TNF-α and IL-1β) [48], and abnormal activation of fibroblast-like synoviocytes (FLSs) [49] are thought to contribute to RA pathogenesis (Fig. 3).

Recently, the involvement of lncRNAs in the pathogenesis of RA has attracted increasing attention. High-throughput analyses by microarray or sequencing revealed that the expression profiles of lncRNAs are altered in the PBMCs [50–52], serum exosomes [51], osteoclasts [51], FLSs [51,53], synovial tissues [54], plasma [55,56], and synovium of a rat model of RA [57]. Some of these differentially expressed lncRNAs are related to disease activity. In CD14 (+) monocytes from RA patients, a large number of lncRNAs exhibited significantly altered expression after either IL-6 or TNF-α inhibition [58]. Aside from human lncRNAs, lncRNA expression in the synovium of rats with adjuvant-induced arthritis (AA) differs from that in the synovium of control rats [59]. In addition, treatment with astragalosides (AST), a traditional Chinese medicine used in the treatment of RA, greatly changes the expression profile of lncRNAs in an AA rat model [60].

HOTAIR is a lncRNA that is widely studied in the cancer field as an important regulator of epigenetic modification; HOTAIR functions by recruiting chromatin modifying complexes [61,62]. The expression of HOTAIR in RA is upregulated in the PBMCs and serum exosomes of patients with RA compared to those of healthy controls, this upregulated expression promotes the migration of macrophages and enhances the recruitment of macrophages to target tissues [51]. On the other hand, HOTAIR expression is decreased in differentiated osteoclasts and RA FLSs, and overexpression of HOTAIR decreases the levels of MMP-2 and MMP-13, which are important players in the process of matrix destruction and joint damage [51]. Further research showed that HOTAIR expression is significantly reduced in chondrocytes after LPS treatment. Overexpression of HOTAIR inhibited the LPS-induced reduction in the cell proliferation rate and IL-17 and IL-23 production by modulating the miR-138 and NF-κB pathways and regulating IL-1β and TNF-α. In addition, similar results have been observed in an RA rat model [63]. These results suggest that HOTAIR may be a promising biomarker and therapeutic target for RA.

Another example of a functional lncRNA is HIX003209, which acts as a ceRNA and exacerbates inflammation by sponging miR-6089 through the TLR4/NF-κB pathway in macrophages [64]. The lncRNA NTT, a lncRNA regulated by the monocyte key transcription factor C/EBPβ, is elevated in rheumatoid arthritis and promotes monocyte differentiation by regulating the nearby gene PBOV1 [65].

lincRNA-p21, which functions as a key repressor of the TP53 target by interacting with ING1b and MDM2, is associated with tumor development and progression and may predict treatment response [66]. In RA, lincRNA-p21 was found to be expressed at a lower level in whole blood samples, while the expression of phosphorylated p65 (RelA), a marker of NF-κB activation, was higher than that in the control. Methotrexate (MTX) treatment in RA patients increases the expression levels of lincRNA-p21 and decreases the levels of p65. An in vitro study using either activated primary T cells or Jurkat cells indicated that lincRNA-p21 was induced via the DNA-dependent protein kinase catalytic subunit (DNA PKcs). Furthermore, MTX modulated NF-κB activity through the induction of lincRNA-p21 [67], suggesting a role of lincRNA-p21 in regulating NF-κB activity.

In T cells from patients with RA, compared with their expression in healthy controls, the lncRNAs LOC100652951, LOC100506036 [68], THRIL, and RMRP [69] are upregulated. RA patients treated with biological agents such as abatacept and tocilizumab show lower expression levels of LOC100652951. The expression of LOC100506036 increases in patients with RA compared to those of healthy controls [68]. THRIL and RMRP are upregulated. RA patients treated with biological agents such as abatacept and tocilizumab show lower expression levels of LOC100652951. The expression of LOC100506036 increases in patients with RA compared to those of healthy controls [68].

Fig. 3. Important lncRNAs involved in the pathogenesis of RA.
activated Jurkat cells, and silencing LOC100506036 reduces the expression of IFN-γ. In addition, the knockdown of LOC100506036 leads to decreased expression of NEAT1, which is a critical regulator of various cytokines [68]. The results above indicate that LOC100506036 could contribute to the inflammatory responses in RA.

The TRAF1-C5 region has been identified as an RA susceptibility gene [70]. The expression level of the IncRNA C5T1, a lncRNA transcribed from the 3′ untranslated region (UTR) of C5, predominantly in the nucleus, shows a positive correlation with C5 mRNA in various tissues and in PBMCs, indicating that C5T1 influences the transcription levels of C5 [71].

The lncRNA H19 is abundantly expressed in embryonal tissue and a number of different tumors [72,73]. In RA synovial tissues, H19 expression is significantly increased relative to that in osteoarthritis (OA) or normal/joint trauma control tissues and is located in the lining layer, diffuse infiltrates, and stroma regions [74]. Synovial macrophages and fibroblasts cultured in vitro also showed elevated expression of H19. Moreover, the expression of H19 is induced in RA FLSs by starvation, which is independent of stimulation with TNF-α, IL-1β or platelet-derived growth factor-factor-BB (PDGF-BB). The expression of H19 is regulated by the PI3K and ERK-1/2 pathways, which are observed to play pivotal roles in the activation of RA FLSs [74]. In contrast, in a Chinese Han population, no association of single nucleotide polymorphisms (SNPs) within H19 with genetic susceptibility to RA was found [75]. Therefore, the roles of H19 in RA pathogenesis still need to be further studied.

Abnormal activation and tumor-like transformation of RA FLSs have been regarded as key steps in joint destruction. AK309896, termed as LERFS (lowlyexpressed in rheumatoid fibroblast-like gyrocytoides), is a novel 1729-nucleotide lncRNA transcribed from chromosome 9q13 and predominantly located in the cytoplasm; LERFS was found to be significantly downregulated in RA FLSs by a microarray screen. PDGFBB treatment induced significant downregulation of LERFS; on the other hand, MTX treatment enhanced the expression of LERFS. In vitro experiments in cultured FLSs proved that LERFS negatively regulates the migration, invasion, and proliferation of FLSs through interaction with heterogeneous nuclear ribonucleoprotein Q (hnRNPQ), which modulates the mRNA stability or translation of RhoA, Rac1, and CDC42 by binding to target mRNAs. In vivo experiments using a nude mouse migration model and a SCID mouse co-implantation invasion model further supported the regulation of RA FLS migration and invasion by LERFS [41].

ZFAS1 is another lncRNA that is involved in the abnormal activation of RA FLSs. Increased expression of ZFAS1 promotes RA FLS migration and invasion by suppressing miR-27a [76]. Similarly, lncRNA GAPLINC [77] and PICSAR [78] participate in the regulation of proliferation, migration and invasion by sponging microRNA molecules. In addition, FER1L4 regulates inflammation in RA FLSs by potentially targeting NLRCS [79]. Several IncRNAs, including MALAT1 [80], UCA1 [81], DILC [82], LncIL7R [83] and LINC00152 [84], have been reported to contribute to apoptosis and proliferation in RA-FLSs. IncRNA GAS5 [85, 86] and ITSN1-2 [87] are implicated in apoptosis and inflammation in RA FLSs. MEG3, a lncRNA that participates in cell proliferation in cancer tissues, also modulates inflammation by targeting NLRCS [88], mir-141 and the AKT/mTOR pathways [89]. In addition, in an RA rat model, PVT1 regulates both inflammation and apoptosis in RA-FLSs through the demethylation of sirt6 [90].

In a murine anti-collagen monoclonal antibody-induced model of RA, shikonin, a major active ingredient isolated from zicao, suppressed the secretion and expression of IL-6, IL-8, and MMPs by enhancing the expression of the lncRNA NR024118 [91], implying a suppressive role of this lncRNA in inflammation; however, the role of the human homologue of lncRNA NR024118 remains to be established.

Accumulating findings provide novel and strong evidence that lncRNAs may be important regulators and potential therapeutic targets in RA. Nevertheless, the role of lncRNAs in RA is not yet fully understood and requires further investigation.

3.2. lncRNAs in SLE

SLE is a common, chronic autoimmune disease with a high incidence rate in women of childbearing age. SLE is characterized by the production of autoantibodies and deposition of immune complexes in various tissues and organs, causing damage to almost all organs and systems of the human body, most commonly the skin, kidney, lung, nervous system and circulatory system. The etiology of SLE, which involves genetic susceptibility, environmental factors, loss of immune tolerance to auto-antigens and perturbations of both innate and adaptive immune systems, is complicated and not yet fully elucidated [92]. Accumulating evidence indicates that lncRNAs might contribute to the pathogenesis of SLE. Comprehensive analyses using microarray or RNA sequencing revealed greatly altered lncRNA expression profiles in the whole blood [93], PBMCs [94], T cells [95], monocyte-derived dendritic cells (moDCs) [96] and plasma [97] of SLE patients compared to those of healthy controls, and the expression of some of these differentially expressed lncRNAs might correlate with the disease activity of SLE patients.

Nuclear enriched abundant transcript 1 (NEAT1), a constitutively and widely expressed lncRNA that is involved in viral infection and innate immunity, is more highly expressed in peripheral blood mononuclear cells (PBMCs) and monocytes in SLE patients compared to those in healthy controls. The expression level of NEAT1 in SLE patients positively correlates with the SLE Disease Activity Index (SLEDAI) score. Further in vitro studies proved that NEAT1 regulates LPS-induced expression of IL-6, CCL2, and CXCL10, which play critical roles in the pathogenesis of SLE by recruiting inflammatory cells through the regulation of the MAPK signaling pathways [98]. A recent study demonstrated that the IncRNA NEAT1-BAFF axis contributes to the activation of B cells and disease progression in SLE [99].

GWASs have identified chromosomal region 1q25 as an SLE susceptibility locus, and this locus harbors the gene that encodes the lncRNA growth arrest-specific transcript 5 (GASS) [100]. GASS is a widely expressed lncRNA with many functions in tumorigenesis [101], glucocorticoid responses [102] and growth arrest in human T cells [103]. In BXSb mice, which spontaneously develop lupus nephritis, 6 SNPs have been found to be correlated with susceptibility to nephritis [104]. Further research shows that the expression levels of GASS are lower in the CD4+ T cells and B cells from patients with SLE compared to those from healthy controls; however, this differential expression is not seen in whole blood leukocytes, indicating that GASS might be differentially controlled in immune cells and function as a regulator in the immune response [105]. Moreover, the expression of GASS is decreased in the plasma of SLE patients compared with that in healthy controls. Furthermore, the expression levels of GASS in plasma are negatively correlated with erythrocyte sedimentation rates (ESR) and SLEDAI-2K scores in SLE patients [106], suggesting an important role of GASS in the pathogenesis of SLE. However, the exact role of GASS in immune cell function and abnormal autoimmunity in SLE needs further clarification.

Linc0949 is a large intergenic noncoding RNA (lncRNA) associated with disease activity and organ damage in SLE. The expression of linc0949 is significantly decreased in the PBMCs of SLE patients compared to those of controls, reduced in SLE patients with cumulative organ damage, and significantly increased after treatment. The expression level of linc0949 is correlated with the SLEDAI score, levels of C3 and incidence of lupus nephritis [107], indicating that linc0949 could be a potential biomarker for diagnosis and for assessing disease activity, organ damage and therapeutic response in SLE. Further research found that the expression of linc0949 is reduced in PBMCs obtained from healthy donors after treatment with Pam3CSK4, a TLR2 ligand, which is unlike the results observed in PBMCs from SLE patients [107], suggesting an abnormal pattern of linc0949 regulation in SLE. In addition, the aberrant expression of several other IncRNAs, including Lnc5150, Lnc3643 and Lnc7514, was found to be associated with laboratory results and disease activity in SLE [108].

In addition to the previous examples, researchers have found several
other candidates that are possibly involved in SLE. MALAT-1 expression is abnormally increased in monocytes from SLE patients compared with those from healthy controls. Additionally, silencing MALAT-1 significantly reduced the expression of IL-21 by regulating the SIRT1 pathway in monocytes of SLE patients compared with those of healthy controls [109]. Bioinformatics analysis revealed that IncRNA CYP2C91 is implicated in SLE pathogenesis by interacting with transcription factor PU.1 (SPI1), MSR1 and CCR1 [110]. IncRNA TUG1 expression is markedly lower in PBMCs of SLE patients compared with that in healthy controls and even lower in SLE patients with LN. The level of TUG1 is correlated with SLEDAI, ESR, disease duration and 24-h urinary protein [111]. In a mouse SLE model, TUG1 was observed to be involved in the protective effect of NF-kB inhibition on kidney injury [112]. Elevated IncRNA RP11-2B6.2 was observed in kidney biopsies from LN patients and positively correlated with disease activity and IFN scores. The knockdown of the IncRNA RP11-2B6.2 in renal cells inhibits the expression of IFN stimulated genes (ISGs) and the phosphorylation of JAK1, TYK2, and STAT1 in the IFN-1 pathway via the epigenetic regulation of SOCS1 [113]. The precise role of these IncRNAs and their underlying biological mechanisms in SLE still require further investigation.

3.3. IncRNAs in IMM

IMMs are a group of heterogeneous disorders that cause damage to multiple organs because of chronic inflammation of skeletal muscle. IMMs mainly comprise four subgroups: dermatomyositis (DM), polymyositis (PM), immune-mediated necrotic myopathy and inclusion body myositis (IBM) [114]. In a study conducted in PM/DM patients, autoantibodies against IncRNA 7 S L, the RNA component of signal recognition particle (SRP), were found to be related to ethnic background, clinical manifestations, and seasonal disease onset [115], suggesting that IncRNA 7 S L is related to the pathogenesis of PM/DM. Transcriptional profiling using microarray analysis identified more than 1000 differentially expressed IncRNAs in DM patients. Bioinformatics prediction suggested that linc-DGCR6-1 may regulate the type 1 interferon-inducible gene USP18 [116]. Fifty-five and 46 IncRNAs are differentially expressed in muscle biopsies obtained from IBM and anti-Jo-1-associated myositis (Jo-1) patients, respectively. H19, IncMycD and MALAT1 are upregulated in both IBM and Jo-1 myositis compared with healthy controls [117]. Taken together, IncRNA expression profiles are aberrantly regulated in IMMs, and further investigation of IncRNA function remains to be done.

3.4. IncRNAs in SSc

SSc is a complex autoimmune disease characterized by changes in the microvasculature and fibrosis of the skin and internal organs. The excessive production of various extracellular matrix proteins, mainly type I collagen, by skin dermal fibroblasts is a critical step in the pathological process in SSc [118]. The IncRNA TSIX is increased in the serum and skin fibroblasts of patients with SSc compared with SLE patients and healthy controls, which may be regulated by the TGF-β signaling pathway. Further studies revealed that TSIX siRNA significantly reduced type I collagen mRNA stability [119], implying a regulatory role of IncRNAs in the tissue fibrosis of SSc. RNA sequencing of skin biopsy samples found that 257 antisense IncRNAs are differentially expressed in early SSc patients compared to healthy individuals [120]. Recently, a comprehensive analysis of IncRNA expression in PBMCs from 20 SSc patients and 20 healthy donors revealed that the IncRNA ncRNA002021 is significantly downregulated in SSc. NcRNA002021 has been reported to regulate tumor proliferation and target the hnRNPGC gene, which encodes an SSc-associated autoantigen. Further bioinformatic analysis of ncRNA002021-targeted microRNAs and genes indicated that ncRNA002021 regulates genes involved in vasculopathy, fibrosis and autoimmunity in SSc [121], providing new insight into disease pathogenesis. TLR activation and IFN-stimulated genes (ISGs) upregulation in PBMCs have been identified as possible contributors to the pathogenesis of SSc. The IncRNA named the Negative Regulator of the IFN Response (NRIR) was found to be significantly upregulated in SSc. In NRIR-silenced monocytes, the expression of CXCL10 and CXCL11, which are two IFN-related chemokines associated with SSc pathogenesis, was reduced, showing that the dysregulation of NRIR in SSc monocytes may be involved in the IFN response pathway in SSc patients [122]. To date, however, knowledge of the IncRNA function and molecular mechanism is still lacking and needs to be further studied.

3.5. IncRNAs in pSS

pSS is an autoimmune disease that occurs predominantly in middle-aged women and is characterized by chronic inflammation in salivary and lacrimal glands; this inflammation is caused by lymphocyte and plasma cell infiltration [123]. The IncRNA IFNGAS (also known as TMEVPG1), which is encoded by a gene located near the Ifn gene, contributes to IFNγ expression. IFNGAS expression is increased in CD4+ T cells from pSS patients compared with those from healthy controls. In addition, the expression level of IFNGAS is correlated with the levels of SAA, ESR and IgG [124]. Examination of the expression profile of IncRNAs in labial salivary glands (LSGs) by microarray identified 1243 differentially expressed IncRNAs in pSS patients. Eight of these differentially expressed IncRNAs, including ENST000004204219.1, ENST00000455309.1, n336161, NR_002712, ENST00000546086.1, Lnc-UTS2D-1-1, n340599, and TCONS_0014794, were confirmed to be upregulated and found to correlate with beta2 microglobulin, disease course, ESR, rheumatoid factor (RF), IgA, IgM, visual analogue scale (VAS) of parotid swelling and VAS of dry eyes [125]. The transcriptome analysis of PBMCs from pSS patients and healthy controls identified 199 differentially expressed IncRNAs. Through a complex network analysis of IncRNA–miRNA–gene functional interactions, three IncRNAs, namely, LINC00657, LINC0051 and CTD-2020K17.1, were identified to be involved in the pathogenesis of pSS [126]. Recently, a study demonstrated that the IncRNA PVT1 is upregulated in the CD4+ T cells of SS patients. PVT1 could maintain the expression of Myc, thus controlling the proliferation and function of CD4+ T cells by regulating the reprogramming of glycolysis, providing a novel mechanistic function of IncRNA PVT1 in the pathogenesis of SS [127].

3.6. IncRNAs in AS

AS is a heritable chronic inflammatory autoimmune disease that leads to the fusion of vertebrae and sacroiliac joints and is characterized by back pain, arthralgia and disability. A total of 661 IncRNAs were found to be differentially expressed in hip joint ligament tissue samples obtained from AS patients compared with those from healthy controls [128]. Recently, IncRNA H19 was found to be upregulated in the PBMCs of AS compared with those of healthy controls. Moreover, H19 modulates the expression of IL-17 A and IL-23 via interaction with miR22-5p and miR675-5p [129], suggesting an important role of IncRNAs in controlling inflammation in AS.

4. Conclusion and future perspectives

As an emerging topic in the field of epigenetic regulation research, IncRNAs have been demonstrated to play critical roles in many physiological and pathological processes via various exquisite mechanisms. With great advances in tumor biology research, IncRNAs are widely regarded as promising biomarkers and therapeutic targets in various types of tumors. However, compared to cancer, IncRNA research in autoimmune diseases is a nascent and developing field. In this review, we summarize the most current knowledge on the function of IncRNAs in the pathogenesis of autoimmune diseases and the underlying molecular mechanisms. A wide spectrum of IncRNAs is observed to be differentially expressed in various autoimmune diseases, including RA, SLE, IMMs, SSc and pSS, and some of these molecules were found to be correlated to
clinical presentations and disease activity, showing the potential of these lncRNAs as biomarkers for diagnosis, treatment and prognosis. However, only a few of these lncRNAs were verified to execute confirmed functions in the process of diseases, and the precise molecular basis of these functions remains largely unknown. Much more intensive research is needed in the future to explore the regulatory pattern responsible for the altered lncRNA expression profiles between different developmental stages, different disease states, different cell types and tissues and the precise functional roles of these lncRNAs. To date, the vast majority of lncRNAs remain poorly defined, and the challenge going forward will be to annotate lncRNA sequences, to identify functional structures and domains, and to elucidate the lncRNA-centered mechanisms and their interaction partners. With advances in molecular biological techniques, the unknown mechanisms by which lncRNA regulate autoimmune diseases will be identified, and disease-related functional lncRNAs could be translated into clinical practice.

Declaration of competing interest

The authors declare that they have no competing interests.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (18171275, 81671591, U1402122); the Fundamental Research Funds for the Central Universities of China (17ykjc07).

References

[1] L. Martin, H.Y. Chang. Uncovering the role of genomic “dark matter” in human disease, J. Clin. Invest. 122 (5) (2012) 1589–1595.
[2] P.G. Maass, F.C. Luft, S. Bahring, Long non-coding RNA in health and disease, J. Mol. Med. (Berl) 92 (4) (2014) 337–346.
[3] J.M. Engreitz, et al., Local regulation of gene expression by lncRNA promoters, transcription and splicing, Nature 539 (7629) (2016) 452–455.
[4] V.R. Paralarak, et al., Unlinking an lncRNA from its associated cis element, Mol. Cell. 62 (1) (2016) 104–110.
[5] M.R. Paralkar, et al., Unlinking an lncRNA from its associated cis element, Mol. Cell. 62 (1) (2016) 104–110.
[6] Y. Okazaki, et al., Analysis of the mouse transcriptome based on functional regulatory DNA, Nature 489 (7414) (2012) 101–108.
[7] K. Struhl, Transcriptional noise and the function, Nat. Rev. Genet. 17 (1) (2016) 47–62.
[8] H. Bierhoff, et al., Noncoding transcripts in sense and antisense orientation of lncRNAs are involved in homeotic gene expression, Nature 539 (7629) (2016) 436–455.
[9] I.B. McInnes, G. Schett, The pathogenesis of rheumatoid arthritis, N. Engl. J. Med. 369 (2013) 2169–2182.
[10] F. Wang, et al., The STAT3-binding long noncoding RNA Inc-DC controls human monocyte cell differentiation, Science 364 (6418) (2019) 310–313.
[11] A. Nitsche, P.F. Stadler, Evolutionary clues in lncRNAs, Wiley Interdiscip Rev RNA 8 (1) (2017) 76–92.
[12] Z. Li, et al., The long noncoding RNA THRIL regulates TNF expression through the interaction with hnRNPL, Proc. Natl. Acad. Sci. U. S. A. 111 (3) (2014) 1273–1278.
[13] M. Cesana, et al., LncRNA UPAT promotes colon tumorigenesis by competing endogenous gene expression, Nature 529 (7629) (2016) 452–455.
[14] C. Yuan, Y. Ning, Y. Pan, Emerging roles of HOAT in human cancer, J. Cell. Biochem. 120 (5) (2019) 8459–8469.
[15] E.P. McInnes, I. Schett, The pathogenesis of rheumatoid arthritis, Cytokine 68 (1) (2014) 65–72.
[16] J.M. Engreitz, et al., Local regulation of gene expression by lncRNA promoters, transcription and splicing, Nature 539 (7629) (2016) 452–455.
[17] V.R. Paralarak, et al., Unlinking an lncRNA from its associated cis element, Mol. Cell. 62 (1) (2016) 104–110.
[18] N.A. Rapicavoli, et al., A mammalian pseudogene IncRNA at the interface of inflammation and anti-inflammatory therapeutics, Elife 2 (2013), e00762.
[19] D.W. Thompson, M.E. Dinger, Endogenous microRNA sponges: evidence and controversy, Nat. Rev. Genet. 17 (5) (2016) 272–283.
[20] S. Sharma, et al., Deregulation of long non-coding RNAs in the mouse brain, Brain Res. 1681 (2015) 134–144.
I.J. Matouk, et al., The oncofetal H19 RNA connection: hypoxia, p53 and cancer, Biochim. Biophys. Acta 1478 (4) (2000) 283–290.

Z. Hj, et al., LncRNA HOTAIR alleviates rheumatoid arthritis by targeting miR-138 and inactivating NF-κB pathway, Int. Immunopharmacol. 50 (2017) 2294–2302.

C.A. Yang, et al., IncRNA NIT/PBO1 Axis promotes monocyte differentiation and is elevated in rheumatoid arthritis, Int. J. Mol. Sci. 19 (9) (2018).

S. Chen, et al., LincRNA-p21: function and mechanism in cancer, Med. Oncol. 34 (96) (2017).

C.F. Surplock, et al., Methotrexate inhibits NF-κB activity via long intergenic (noncoding) RNA p21 induction, Arthritis & Rheumatology 66 (6) (2014) 2947–2957.

M. Lu, et al., Increased expression of long noncoding RNAs LOC100652951 and LOC100506036 in T cells from patients with rheumatoid arthritis facilitates the inflammatory responses, Immunol. Res. 64 (2) (2016) 576–583.

M. Moharamgholi, et al., The expression of GAS5, THRL, and RMRP IncRNAs is increased in T cells from patients with rheumatoid arthritis, Clin. Rheumatol. 38 (11) (2019) 3073–3080.

F.A.S. Kurreeman, et al., A candidate gene approach identifies the TRAF1/CS region as a risk factor for rheumatoid arthritis, PLoS Med. 4 (e2789) (2007) 1515–1520.

T.C. Messamaker, et al., A novel long non-coding RNA in the rheumatoid arthritis risk locus TRAF1-CS influences CS mRNA levels, Gene Immun. (17) (2016) 85–92.

S. Ayeh, et al., Possible physiological role of H19 RNA, Mol. Carcinog. 35 (2) (2002) 63–74.

L.J. Matouk, et al., The oncogenic H19 RNA connection: hypoxia, p53 and cancer, Biochim. Biophys. Acta 1803 (4) (2010) 443–453.

B. Schmülling, et al., Detection of oncogenic H19 RNA in rheumatoid arthritis synovial tissue, Am. J. Pathol. 163 (3) (2003) 901–911.

H. Af, et al., Association of no specific nucleotide polymorphisms within H19 and HOX transcript antisense RNA (HOTAIR) with genetic susceptibility to systemic lupus erythematosus, rheumatoid arthritis, and primary Sjogren’s syndrome in a Chinese Han population, Clin. Rheumatol. 36 (11) (2017) 2447–2453.

Y. Ye, X. Gao, N. Yang, LncRNA ZFAS1 promotes cell migration and invasion of fibroblast-like synoviocytes by suppression of miR-27a in rheumatoid arthritis, Adv. Cell Biol. 31 (11) (2018) 14–21.

B.Y. Mo, et al., Long non-coding RNA GAPLINC promotes tumor-like biologic behaviors of fibroblast-like synoviocytes as MicroRNA sponging in rheumatoid arthritis patients, Front. Immunol. 9 (2018) 702.

X. Bi, et al., LncRNA PICSAR promotes cell proliferation, migration and invasion of fibroblast-like synoviocytes by sponging miR-4701-5p in rheumatoid arthritis, Eli Lilly Medicine 50 (2019) 408–420.

Y. Ji, et al., Long Noncoding RNA FERL14 regulates Rheumatoid Arthritis via Targeting NLRC5, Clinical and experimental rheumatology, 2019.

F. Pan, et al., Quercetin promotes the apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis by up-regulating IncRNA MALAT1, Int. J. Mol. Sci. 38 (5) (2019) 430–443.

Z.F. Yan, et al., UCA1 impacts progress of rheumatoid arthritis by inducing the apoptosis of fibroblast-like synoviocytes, Eur. Rev. Med. Pharmacol. Sci. 22 (4) (2018) 914–920.

G. Wang, et al., LncRNA DLIC participates in rheumatoid arthritis by inducing apoptosis of fibroblast-like synoviocytes and down-regulating IL-6, Biochem. Biophys. Rep. 39 (5) (2019).

Y. Z, et al., Lnc-IL7R promotes the growth of fibroblast-like synoviocytes through interaction with enhancer of zeste homolog 2 in rheumatoid arthritis, Mol. Med. Rep. 15 (3) (2017) 1412–1418.

W. Wang, et al., FOXMI1/JNC00152 feedback loop regulates proliferation and apoptosis in rheumatoid arthritis fibroblast-like synoviocytes via Wnt/beta-catenin signaling pathway, Biochem. Biophys. Rep. 40 (9) (2019) 1066–1075.

G. Li, et al., Tanshinone IIA promotes the apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis by up-regulating IncRNA GAS5, Biochem. Biophys. Rep. 38 (5) (2018).

C. Ma, W. Wang, P. Li, LncRNA GAS5 overexpression downregulates IL-18 and induces the apoptosis of fibroblast-like synoviocytes, Clin. Rheumatol. 38 (11) (2019) 3275–3280.

T. Yue, et al., Downregulation of IncRNA ITSN1-2 correlates with decreased disease risk and activity of rheumatoid arthritis (RA), and reduces RA fibroblast-like synoviocytes proliferation and inflammation via inhibiting NOGZ/RIP2 signaling pathway, Am J Transl Res 11 (8) (2019) 4560–4666.

D. Yr, et al., Long noncoding RNA MEG3 regulates rheumatoid arthritis by targeting IRES2, FEBS Lett. 574 (1) (2019) 2181–2185.

G. Li, et al., LncRNA MEG3 inhibits rheumatoid arthritis through miR-141 and inactivation of AKT/MTOR signalling pathway, J. Cell. Mol. Med. 23 (10) (2019) 7116–7120.

G.W. Chang, et al., Long non-coding RNA PVT1 knockdown suppresses fibroblast-like synoviocyte inflammation and induces apoptosis in rheumatoid arthritis through demethylation of sirt6, J. Biol. Eng. 13 (2019) 60.
(vasculopathy, fibrosis and autoimmunity) and in carcinogenesis, J. Clin. Med. 8 (3) (2019).

[122] B. Mariotti, et al., The long non-coding RNA NRIR drives IFN-response in monocytes: implication for systemic sclerosis, Front. Immunol. 10 (2019) 100.

[123] P. Brito-Zeron, et al., Sjogren syndrome, Nat Rev Dis Primers 2 (2016) 16047.

[124] J. Wang, et al., Upregulation of long noncoding RNA TMEVPG1 enhances T helper type 1 cell response in patients with Sjogren syndrome, Immunol. Res. 64 (2) (2016) 489–496.

[125] H. Shi, et al., Long non-coding RNA expression profile in minor salivary gland of primary Sjogren’s syndrome, Arthritis Res. Ther. 18 (1) (2016) 109.

[126] M. Dolcino, et al., Long non-coding RNAs modulate sjogren’s syndrome associated gene expression and are involved in the pathogenesis of the disease, J. Clin. Med. 8 (9) (2019).

[127] F. J, et al., LncRNA PVT1 links Myc to glycolytic metabolism upon CD4 T cell activation and Sjogren’s syndrome-like autoimmune response, J. Autoimmun. (2019), 102358.

[128] C. Zhang, et al., Differentially expressed mRNAs, lncRNAs, and miRNAs with associated co-expression and ceRNA networks in ankylosing spondylitis, Oncotarget 8 (69) (2017) 113543–113557.

[129] X. Z, et al., H19 increases IL-17a/IL-23 releases via regulating VDR by interacting with miR875-5p/miR22-5p in ankylosing spondylitis. Molecular therapy, Nucleic acids 19 (2019) 393-404.